'A New TNBC Standard Of Care' – Trodelvy Could Vindicate Gilead’s $21bn Buyout

Survival Gains In Third Line Patients

 
• By Andrew McConaghie
Gilead HQ
Gilead's $21bn acquisition of Immunomedics is set for completion by the end of 2020.

More from Anticancer

More from Therapeutic Category